摘要
目的 为临床安全使用阿格列汀提供参考。方法 检索中国知网、万方、维普、PubMed、Web of Science数据库自建库起至2023年12月31日收录的阿格列汀药品不良反应(ADR)个案报道,分析ADR特点,并分别按诺氏(Naranjo′s)评估量表和美国国家用药错误报告及预防协调委员会用药错误分级进行关联性和严重程度评价。结果 共纳入11篇文献,收集11例(国外9例,国内2例)ADR病例,其中男9例,女2例,年龄31~77岁,平均(60.82±12.00)岁;ADR多于用药后1个月内发生(5例,45.45%);主要累及皮肤及其附件(5例,45.45%)和消化系统(3例,27.27%),主要ADR为大疱性类天疱疮(3例,27.27%),血管性水肿(2例,18.18%)和急性胰腺炎(2例,18.18%)。微小病变肾病综合征和间质性肾炎、口腔炎为该药新的ADR。经停药或对症处理后10例(90.91%)患者好转,1例死亡。Naranjo′s评分为4-9分,平均6.36分,关联性分析结果为肯定有关1例,很可能有关8例,可能有关2例。美国国家用药错误报告及预防协调委员会用药错误分级结果显示E级1例,F级9例,I级1例。结论 临床医师应重视阿格列汀所致ADR的危害,加强药学监护,保证患者的用药安全。
Objective To provide a reference for safe clinical use of alogliptin.Methods Case reports of alogliptin-induced adverse drug reaction(ADR)in the CNKI,WanFang,VIP,PubMed,and Web of Science databases were searched from the establishment of each database to December 31,2023,the characteristics of ADR were analyzed,and the correlation and severity were evaluated according to Naranjo′s assessment scale and the classification of medication errors(ME)of National Coordinating Council for Medication Error Reporting and Prevention(NCCMERP)of the United States.Results A total of 11 reports were included,involving 11 ADR cases(nine cases overseas,two cases domestic),including nine males and two females,the age was in the range of 31-77 years old,with an average of(60.82±12.00)years;ADR mostly occured within one month after medication(five cases,45.45%);the systems/organs mainly involved the skin and its accessories(five cases,45.45%)and digestive system(three cases,27.27%);the main ADR were bullous pemphigoid(three cases,27.27%),angioedema(two cases,18.18%)and acute pancreatitis(two cases,18.18%).Minimally pathological nephrotic syndrome,interstitial nephritis and stomatitis were the new ADR of this drug.10 cases improved after discontinuing medication or symptomatic treatment,and one cases died.Naranjo′s score was 4-9 points,with an average of 6.36 points.The correlation evaluation showed that there were one positive case,eight very possible cases,and two possible cases.The classification of ME of NCCMERP showed that one case was grade E,nine cases were grade F and one case was grade I.Conclusion Clinicians should pay attention to the hazard of ADR caused by alogliptin,strengthen pharmaceutical care and ensure the safety of patients′medication.
作者
张涛
郑明琳
杨晗
陈鹏霖
冯静
何璐璐
金朝辉
ZHANG Tao;ZHENG Minglin;YANG Han;CHEN Penglin;FENG Jing;HE Lulu;JIN Zhaohui(West China Hospital of Sichuan University,Chengdu,Sichuan,China 610041)
出处
《中国药业》
2025年第18期121-126,共6页
China Pharmaceuticals
基金
四川省科普培训项目[2024JDKP0189]。
关键词
阿格列汀
药品不良反应
文献分析
药学监护
用药安全
alogliptin
adverse drug reaction
literature analysis
pharmaceutical care
medication safety
